Literature DB >> 2441168

Serotonin receptor activation of phosphoinositide turnover in uterine, fundal, vascular, and tracheal smooth muscle.

M L Cohen, L A Wittenauer.   

Abstract

Hydrolysis of phosphatidylinositol is becoming recognized as the second messenger system for a number of hormones and neurotransmitters, including serotonin. The present study was designed to explore the effects of serotonin to enhance phosphoinositide turnover in several smooth muscle preparations, in an effort (a) to determine which smooth muscle preparation might provide a useful system for further study of phosphoinositide turnover and (b) to examine the role of 5-HT2 receptors in such responses. Basal-[3H]inositol monophosphate ([3H]IP) formation was 10-fold higher in the uterus than in the rat jugular vein, aorta, stomach fundus, or guinea pig trachea. Serotonin produced significant elevations in [3H]IP in the rat aorta, uterus, and jugular vein. Maximal elevation in [3H]IP was greatest in the jugular vein (eightfold increase) with an ED50 for serotonin of 0.4 microM. Serotonin (10(-7)-10(-4) M), although a potent contractile agonist in both the guinea pig trachea and rat stomach fundus, did not increase [3H]IP levels in these tissues. The selective 5-HT2 receptor blocker LY53857 (10(-8) M) antagonized the increase in [3H]IP produced by serotonin in the jugular vein, aorta, and uterus. Pargyline (10(-5) M) added to the trachea and fundus did not unmask an effect of serotonin or enhance the response to serotonin in the rat aorta. Thus, the jugular vein was the tissue most sensitive to activation of [3H]IP by serotonin. Increases in [3H]IP produced by serotonin may be linked to activation of 5-HT2 receptors in the jugular vein, aorta, and uterus since the selective 5-HT2 antagonist LY53857 could block this biochemical effect.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2441168     DOI: 10.1097/00005344-198708000-00007

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

1.  Serotonin regulates 6-phosphofructo-1-kinase activity in a PLC-PKC-CaMK II- and Janus kinase-dependent signaling pathway.

Authors:  Wagner Santos Coelho; Mauro Sola-Penna
Journal:  Mol Cell Biochem       Date:  2012-09-26       Impact factor: 3.396

2.  Mechanisms intrinsic to 5-HT2B receptor-induced potentiation of NMDA receptor responses in frog motoneurones.

Authors:  Alice M Holohean; John C Hackman
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

3.  Action of angiotensin II, 5-hydroxytryptamine and adenosine triphosphate on ionic currents in single ear artery cells of the rabbit.

Authors:  A D Hughes; T B Bolton
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 4.  Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome.

Authors:  C Stasi; M Bellini; G Bassotti; C Blandizzi; S Milani
Journal:  Tech Coloproctol       Date:  2014-01-15       Impact factor: 3.781

5.  The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors.

Authors:  D W Bonhaus; C Bach; A DeSouza; F H Salazar; B D Matsuoka; P Zuppan; H W Chan; R M Eglen
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

6.  5-Hydroxytryptamine receptor-mediated phosphoinositide hydrolysis in canine cultured tracheal smooth muscle cells.

Authors:  C M Yang; Y L Yo; J T Hsieh; R Ong
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

7.  Importance of inositol (1,4,5)-trisphosphate, intracellular Ca2+ release and myofilament Ca2+ sensitization in 5-hydroxytryptamine-evoked contraction of rabbit mesenteric artery.

Authors:  J M Seager; T V Murphy; C J Garland
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

8.  Cloning and functional characterization of the rat stomach fundus serotonin receptor.

Authors:  M Foguet; D Hoyer; L A Pardo; A Parekh; F W Kluxen; H O Kalkman; W Stühmer; H Lübbert
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.